{"id":"levagen","safety":{"commonSideEffects":[{"rate":null,"effect":"Local skin irritation"},{"rate":null,"effect":"Allergic contact dermatitis"}]},"_chembl":{"chemblId":"CHEMBL417675","moleculeType":"Small molecule","molecularWeight":"299.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levamisole is an immunostimulant that activates macrophages, enhances T-cell function, and promotes local immune responses. When formulated as Levagen+, it is applied topically to support tissue repair and healing, particularly in chronic or difficult-to-heal wounds. The drug works by restoring impaired immune function at the wound site.","oneSentence":"Levagen+ is a topical formulation containing levamisole that enhances immune function and promotes wound healing through immunomodulatory mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:51:47.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic wounds and ulcers"},{"name":"Wound healing promotion"}]},"trialDetails":[{"nctId":"NCT07359534","phase":"NA","title":"Training Health Recovery and Improvement Via Levagen+® Evaluation","status":"RECRUITING","sponsor":"University of Westminster","startDate":"2025-03-10","conditions":"Exercise Recovery","enrollment":20},{"nctId":"NCT07315516","phase":"PHASE2","title":"Sleep and Stress Study","status":"NOT_YET_RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2026-02","conditions":"Sleep Disorder (Disorder), Stress, Anxiety","enrollment":240},{"nctId":"NCT06717867","phase":"PHASE2","title":"Long-Term PEA Safety Study","status":"RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-01-22","conditions":"Healthy, Safety","enrollment":200},{"nctId":"NCT05480072","phase":"EARLY_PHASE1","title":"Endocannabinoids, Stress, Craving And Pain Effects Study","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT07028528","phase":"PHASE2","title":"Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy","status":"RECRUITING","sponsor":"RDC Clinical Pty Ltd","startDate":"2025-07-01","conditions":"Diabetic Peripheral Neuropathy","enrollment":80},{"nctId":"NCT06351917","phase":"PHASE4","title":"Effect of Topical PlexoZome® Levagen® Spray on Relief of Post Exercise Knee Joint Pain","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2024-04-24","conditions":"Knee Joint Pain","enrollment":80},{"nctId":"NCT05810116","phase":"PHASE4","title":"Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2023-05-19","conditions":"Menstrual Pain","enrollment":80},{"nctId":"NCT06225440","phase":"NA","title":"Impact of Levagen+® Palmitoylethanolamide (PEA) in a Cross-Over Trial Examining Stress and Cognition in University Students","status":"COMPLETED","sponsor":"University of Westminster","startDate":"2022-09-01","conditions":"Wellness, Psychological, Well-Being, Psychological","enrollment":64},{"nctId":"NCT05753111","phase":"NA","title":"Effect of PEA on Muscle Recovery Following Resistance Exercise","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2023-02-16","conditions":"Muscle Recovery, Muscle Soreness","enrollment":11},{"nctId":"NCT05003453","phase":"PHASE2, PHASE3","title":"The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2021-11-29","conditions":"Eczema, Atopic","enrollment":72},{"nctId":"NCT05046522","phase":"PHASE3","title":"A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2021-09-01","conditions":"Migraine","enrollment":80},{"nctId":"NCT04912921","phase":"NA","title":"Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2020-10-20","conditions":"Inflammation, COVID19","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Levagen+","genericName":"Levagen+","companyName":"RDC Clinical Pty Ltd","companyId":"rdc-clinical-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levagen+ is a topical formulation containing levamisole that enhances immune function and promotes wound healing through immunomodulatory mechanisms. Used for Chronic wounds and ulcers, Wound healing promotion.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}